This review discusses challenges to stability, analytics and manufacturing of protein coformulations. Furthermore, general considerations to be taken into account for the pharmaceutical development of coformulated protein drug products are highlighted.
Coformulation of two or more active substances in one single dosage form has recently seen increasing use offering several advantages, such as increased efficacy and/or the overall reduction of adverse event incidents in patients. Most marketed coformulated drug products are composed of small molecules. As proteins are not only comparatively large but also complex molecules, the maintenance of their physicochemical integrity within a formulation throughout pharmaceutical processing, storage, transport, handling and patient administration to ensure proper pharmacokinetics and pharmacodynamics in vivo already represents various challenges for single-entity products. Thus, nowadays, only sparse biologics-based coformulations can be found, as additional complexity during development is given for these products.
The complexity of the dosage form and the protein molecules results into additional challenges to formulation, manufacture, storage, transport, handling and patient administration, stability and analytics during the pharmaceutical development of protein coformulations. Various points have to be considered during different stages of development in order to obtain a safe and efficacious product.
TY - JOUR
AU - Mueller, Claudia
AU - Altenburger, Ulrike
AU - Mohl, Silke
TI - Challenges for the pharmaceutical technical development of protein coformulations
JO - Journal of Pharmacy and Pharmacology
JA - J Pharm Pharmacol
SN - 2042-7158
UR - http://dx.doi.org/10.1111/jphp.12731
DO - 10.1111/jphp.12731
SP - n/a
EP - n/a
KW - dosage form design and characterization
KW - pharmaceutical analysis
KW - pharmaceutics and drug delivery